Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901184 | 0.75 | CASP3 (0.43) | CASP3IDH1NSD2KDM4EALDH1A1 | |
| SCHEMBL16019366 | 0.72 | ALDH1A1 (0.39) | CA1CA2KDM4EALDH1A1GAA | |
| SCHEMBL22402990 | 0.71 | CA12 (0.38) | L3MBTL1ELANECA1ALDH1A1GAA | |
| SCHEMBL22403089 | 0.71 | HSP90AA1 (0.31) | CA1GAA | |
| SCHEMBL12890152 | 0.70 | ACACB (0.46) | CASP3IDH1NSD2KDM4EALDH1A1 | |
| SCHEMBL16019374 | 0.68 | CA2 (0.39) | L3MBTL1CA2KIF11ALDH1A1GAA | |
| SCHEMBL16019333 | 0.68 | KDM4E (0.32) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL23287328 | 0.67 | ADORA2A (0.40) | CASP3IDH1L3MBTL1CA1CA2 | |
| SCHEMBL29311672 | 0.66 | MCHR1 (0.41) | ELANECYP19A1 | |
| SCHEMBL16019329 | 0.66 | MCHR1 (0.46) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542275-B2 | Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-03 | — | — | US | disclosed |
| US-20210002298-A1 | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542275-B2 | Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors | PRMT5, PRMT1, PRMT8 | CASP3 2661/4885IDH1 287/4885L3MBTL1 2943/4885 |
| US-20210002298-A1 | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT8 | CASP3 2661/4885IDH1 287/4885L3MBTL1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.